Drug intelligence / Profile preview

finerenone

Development stage: Approved
Lead developer: Bayer
Modality: Small Molecules

Overview

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) used primarily for the treatment of chronic kidney disease (CKD) in adults with type 2 diabetes. It works by blocking the effects of aldosterone, thereby reducing inflammation and fibrosis in the kidneys and heart. Finerenone is developed by Bayer and has shown efficacy in reducing cardiovascular events and slowing kidney function decline in CKD patients.

Brand names: Kerendia
Other names: 非奈利酮finerenone

Targets

MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on finerenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on finerenone.

Explore the full profile